DigestRedComo funciona
Red
/
Empresas
Mo
No verificado

MoonLake Immunotherapeutics AG

Sobre qué escribimos

Anuncios brevesBiotecnologíaGestión empresarial/Administración de EmpresasMedicina Salud BienestarPublicidad/Marketing/Medios de comunicación/Comunicación

18 Comunicados de prensa

Ver todos los comunicados de prensa
10/08/2026
Biotecnología
Anuncios breves
Gestión empresarial/Administración de Empresas
MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results
Fuente
MoonLake Immunotherapeutics AG
Editor
GLOBENEWSWIRE
1.00
0
21/06/2026
Biotecnología
Medicina Salud Bienestar
Anuncios breves
MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026
Fuente
MoonLake Immunotherapeutics AG
Editor
GLOBENEWSWIRE
1.00
0
10/05/2026
Biotecnología
Anuncios breves
MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results
Fuente
MoonLake Immunotherapeutics AG
Editor
GLOBENEWSWIRE
1.00
0
28/03/2026
Biotecnología
Medicina Salud Bienestar
Anuncios breves
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
Fuente
MoonLake Immunotherapeutics AG
Editor
GLOBENEWSWIRE
1.00
0
22/02/2026
Biotecnología
Anuncios breves
Medicina Salud Bienestar
MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results
Fuente
MoonLake Immunotherapeutics AG
Editor
GLOBENEWSWIRE
1.00
0
02/02/2026
Biotecnología
Anuncios breves
Publicidad/Marketing/Medios de comunicación/Comunicación
MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day
Fuente
MoonLake Immunotherapeutics AG
Editor
GLOBENEWSWIRE
1.00
0
08/01/2026
Biotecnología
Publicidad/Marketing/Medios de comunicación/Comunicación
Anuncios breves
MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day
Fuente
MoonLake Immunotherapeutics AG
Editor
GLOBENEWSWIRE
1.00
0
05/11/2025
Biotecnología
Publicidad/Marketing/Medios de comunicación/Comunicación
Anuncios breves
MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering
Fuente
MoonLake Immunotherapeutics AG
Editor
GLOBENEWSWIRE
1.00
0
05/11/2025
Biotecnología
Publicidad/Marketing/Medios de comunicación/Comunicación
Anuncios breves
MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab
Fuente
MoonLake Immunotherapeutics AG
Editor
GLOBENEWSWIRE
1.00
0
28/09/2025
Biotecnología
Anuncios breves
Publicidad/Marketing/Medios de comunicación/Comunicación
MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody® sonelokimab
Fuente
MoonLake Immunotherapeutics AG
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0